204 related articles for article (PubMed ID: 37086892)
21. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
[TBL] [Abstract][Full Text] [Related]
22.
Karlowsky JA; Hackel MA; Wise MG; Six DA; Uehara T; Daigle DM; Cusick SM; Pevear DC; Moeck G; Sahm DF
Antimicrob Agents Chemother; 2023 Jan; 67(1):e0128122. PubMed ID: 36541767
[TBL] [Abstract][Full Text] [Related]
23. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
Kresken M; Körber-Irrgang B; Korte-Berwanger M; Pfennigwerth N; Gatermann SG; Seifert H;
Int J Antimicrob Agents; 2020 Jun; 55(6):105959. PubMed ID: 32325200
[TBL] [Abstract][Full Text] [Related]
24. Susceptibility of Gram-negative isolates collected in South Korea to imipenem/relebactam and comparator agents-SMART 2018-21.
Karlowsky JA; Wise MG; Chen WT; Siddiqui F; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2024 Feb; 6(1):dlad149. PubMed ID: 38161963
[TBL] [Abstract][Full Text] [Related]
25.
Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Sahm DF
J Med Microbiol; 2020 Feb; 69(2):207-217. PubMed ID: 31976856
[No Abstract] [Full Text] [Related]
26. [Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
Çakar A; Akyön Y; Gür D; Karatuna O; Öğünç D; Özhak Baysan B; Çöplü N; Çağatay M; Kılıç A; Baysallar M; Bakıcı Z; Çelik C; Gülay Z; Aydemir Ş; Tünger A; Kılıç H; Erçal BD; Aşçı Toraman Z; Zer Y; Büyüktaş A; Ay S; Aktaş Z; Kayacan Ç; Bayramoğlu G; Aydın F; Dündar D; Hasdemir U; Ayaş R; Yanık K; Günaydın M; Güdücüoğlu H; Parlak M
Mikrobiyol Bul; 2016 Jan; 50(1):21-33. PubMed ID: 27058326
[TBL] [Abstract][Full Text] [Related]
27. Carbapenem-Nonsusceptible
Asempa TE; Nicolau DP; Kuti JL
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31118271
[No Abstract] [Full Text] [Related]
28. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
29. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021.
Karlowsky JA; Lob SH; Hawser SP; Kothari N; Siddiqui F; Alekseeva I; DeRyke CA; Young K; Motyl MR; Sahm DF
Eur J Clin Microbiol Infect Dis; 2024 May; ():. PubMed ID: 38775873
[TBL] [Abstract][Full Text] [Related]
30. Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of
Lob SH; DePestel DD; DeRyke CA; Kazmierczak KM; Young K; Motyl MR; Sahm DF
Open Forum Infect Dis; 2021 Jul; 8(7):ofab320. PubMed ID: 34307727
[TBL] [Abstract][Full Text] [Related]
31. Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020.
García-Fernández S; Calvo J; Cercenado E; Suárez-Barrenechea AI; Fernández-Billón M; Castillo FJ; Gálvez-Benítez L; Tubau F; Figueroa Cerón RE; Hernández-Cabezas A; González Romo F; Fariñas MC; Gómez M; Díaz-Regañón J; Cantón R
Rev Esp Quimioter; 2023 Jun; 36(3):302-309. PubMed ID: 36951688
[TBL] [Abstract][Full Text] [Related]
32.
Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
[TBL] [Abstract][Full Text] [Related]
33. Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019.
Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
BMC Microbiol; 2021 Mar; 21(1):74. PubMed ID: 33676406
[TBL] [Abstract][Full Text] [Related]
34. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
[TBL] [Abstract][Full Text] [Related]
35. Antimicrobial susceptibility testing of clinical isolates of Gram-negative bacilli collected in Morocco by the ATLAS Global Surveillance Program from 2018 to 2020.
Karlowsky JA; Bouchillon SK; Benaouda A; Soraa N; Zerouali K; Mohamed N; Alami T; Sahm DF
J Glob Antimicrob Resist; 2022 Sep; 30():23-30. PubMed ID: 35447385
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
Chang CY; Lee YL; Huang YT; Ko WC; Ho MW; Hsueh PR
Int J Antimicrob Agents; 2023 Jun; 61(6):106815. PubMed ID: 37059343
[TBL] [Abstract][Full Text] [Related]
37. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
[TBL] [Abstract][Full Text] [Related]
38. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018).
Cantón R; Loza E; Arcay RM; Cercenado E; Castillo FJ; Cisterna R; Gálvez-Benítez L; González Romo F; Hernández-Cabezas A; Rodríguez-Lozano J; Suárez-Barrenechea AI; Tubau F; Díaz-Regañón J; López-Mendoza D;
Rev Esp Quimioter; 2021 Jun; 34(3):228-237. PubMed ID: 33645948
[TBL] [Abstract][Full Text] [Related]
40.
Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]